Literature DB >> 3865750

Association of HLA antigens with thyrotoxic Graves' disease and periodic paralysis in Hong Kong Chinese.

B R Hawkins, J T Ma, K S Lam, C C Wang, R T Yeung.   

Abstract

The HLA-A and -B antigen distribution in 132 Hong Kong Chinese patients with Graves' disease, including 24 with thyrotoxic periodic paralysis, was compared with that in 110 controls. The HLA-DR antigen distribution in 68 patients was compared with that in 47 controls. The prevalence of Bw46 was significantly increased in patients with Graves' disease and with periodic paralysis. The prevalence of DRw9 was also slightly increased but not at a statistically significant level. The high prevalence of Bw46 related to patients with early age at onset whereas patients with later age at onset had a significantly increased prevalence of HLA B5. It is suggested that Graves' disease in Chinese is due to two HLA-associated mechanisms in which early-onset disease is associated with Bw46 and late-onset disease with B5.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3865750     DOI: 10.1111/j.1365-2265.1985.tb00220.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  12 in total

1.  In vivo and in vitro sodium pump activity in subjects with thyrotoxic periodic paralysis.

Authors:  A Chan; R Shinde; C C Chow; C S Cockram; R Swaminathan
Journal:  BMJ       Date:  1991-11-02

2.  Effects of sex steroid hormones, thyroid hormone levels, and insulin regulation on thyrotoxic periodic paralysis in Chinese men.

Authors:  Wang Li; Chen Changsheng; Fu Jiangfang; Gao Bin; Zhang Nanyan; Li Xiaomiao; Li Deqiang; Xing Ying; Zai Wensong; Ji Qiuhe
Journal:  Endocrine       Date:  2010-10-23       Impact factor: 3.633

Review 3.  Novel etiopathophysiological aspects of thyrotoxic periodic paralysis.

Authors:  Rui M B Maciel; Susan C Lindsey; Magnus R Dias da Silva
Journal:  Nat Rev Endocrinol       Date:  2011-05-10       Impact factor: 43.330

4.  The inter-locus recombinant HLA-B*4601 has high selectivity in peptide binding and functions characteristic of HLA-C.

Authors:  L D Barber; L Percival; N M Valiante; L Chen; C Lee; J E Gumperz; J H Phillips; L L Lanier; J C Bigge; R B Parekh; P Parham
Journal:  J Exp Med       Date:  1996-08-01       Impact factor: 14.307

5.  Human lymphocyte antigens (HLA) and Graves' disease in Turkey.

Authors:  Y Orhan; A Azezli; M Carin; F Aral; E Sencer; S Molvalilar
Journal:  J Clin Immunol       Date:  1993-09       Impact factor: 8.317

6.  Comprehensive genotyping in two homogeneous Graves' disease samples reveals major and novel HLA association alleles.

Authors:  Pei-Lung Chen; Cathy Shen-Jang Fann; Chen-Chung Chu; Chien-Ching Chang; Su-Wei Chang; Hsin-Yi Hsieh; Marie Lin; Wei-Shiung Yang; Tien-Chun Chang
Journal:  PLoS One       Date:  2011-01-28       Impact factor: 3.240

Review 7.  Thyrotoxic periodic paralysis: an overview.

Authors:  Chang-Hsun Hsieh; Shi-Wen Kuo; Dee Pei; Yi-Jen Hung; Sandra Chyi-Fan; Ling-I Wu; Chih-Tsueng He; Tsao-Chin Yang; Wei-Cheng Lian; Lee Chien-Hsing
Journal:  Ann Saudi Med       Date:  2004 Nov-Dec       Impact factor: 1.526

8.  Autoimmune thyroid disease following hematopoietic stem cell transplantation in childhood cancer survivors.

Authors:  Shunsuke Shimazaki; Itsuro Kazukawa; Masanori Minagawa
Journal:  Clin Pediatr Endocrinol       Date:  2021-12-16

9.  Association between HLA-B*46 allele and Graves disease in Asian populations: a meta-analysis.

Authors:  Yiping Li; Yufeng Yao; Man Yang; Li Shi; Xianli Li; Ying Yang; Ying Zhang; Chunjie Xiao
Journal:  Int J Med Sci       Date:  2013-01-03       Impact factor: 3.738

10.  The Intergenic Recombinant HLA-B∗46:01 Has a Distinctive Peptidome that Includes KIR2DL3 Ligands.

Authors:  Hugo G Hilton; Curtis P McMurtrey; Alex S Han; Zakia Djaoud; Lisbeth A Guethlein; Jeroen H Blokhuis; Jason L Pugh; Ana Goyos; Amir Horowitz; Rico Buchli; Ken W Jackson; Wilfred Bardet; David A Bushnell; Philip J Robinson; Juan L Mendoza; Michael E Birnbaum; Morten Nielsen; K Christopher Garcia; William H Hildebrand; Peter Parham
Journal:  Cell Rep       Date:  2017-05-16       Impact factor: 9.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.